Who Buys Osimertinib from India — 50 Importers Behind a $1.1M Market

The importation of Osimertinib from India involves various buyer segments, each with distinct purchasing behaviors:

• Hospital Groups: Entities like the Indira Gandhi Memorial Hospital in the Maldives fall into this category. They procure Osimertinib directly to meet patient needs, often placing orders based on current demand and treatment protocols. Their purchasing patterns are typically consistent, aligning with patient intake and treatment schedules.

• Distributors: Buyers such as "To the Concern Person" in Brazil and Incepta Pharmaceuticals Ltd in Bangladesh act as intermediaries, supplying Osimertinib to healthcare providers and pharmacies. They tend to place larger, periodic orders to maintain inventory levels and meet market demand.

• Individual Buyers: Several Brazilian buyers, including "Concern Person Wanilda De," "To The," and "Guilherme Martins De Almeida," appear to be individual purchasers. Their orders are typically smaller and less frequent, likely driven by personal or immediate community needs.

Understanding these segments is crucial for tailoring marketing strategies and supply chain logistics to effectively meet the diverse demands of each buyer type.

Importing Osimertinib into the top five countries involves navigating specific regulatory frameworks:

• Brazil:
• Regulatory Authority: Agência Nacional de Vigilância Sanitária (ANVISA).
• Import Registration Process: Requires submission of a comprehensive dossier, including clinical data and manufacturing details, followed by ANVISA's evaluation and approval.
• Estimated Timeline: Approximately 6 to 12 months, depending on the completeness of the application and ANVISA's review workload.
• Import Tariff/Duty: Pharmaceutical products under HS Code 30049099 are subject to a standard import duty, which may vary based on trade agreements and specific product classifications.

• United Kingdom:
• Regulatory Authority: Medicines and Healthcare products Regulatory Agency (MHRA).
• Import Registration Process: Requires a Marketing Authorization (MA), involving submission of quality, safety, and efficacy data.
• Estimated Timeline: Typically 6 to 12 months, subject to the complexity of the application and MHRA's assessment process.
• Import Tariff/Duty: Medicaments under HS Code 30049099 are generally subject to the UK's standard import duties, with specific rates depending on trade agreements and product specifics.

• Maldives:
• Regulatory Authority: Maldives Food and Drug Authority (MFDA).
• Import Registration Process: Involves submission of product dossiers, including manufacturing and clinical data, for MFDA's evaluation.
• Estimated Timeline: Approximately 3 to 6 months, depending on the completeness of the submission and MFDA's review process.
• Import Tariff/Duty: Pharmaceuticals under HS Code 30049099 may be subject to import duties, with rates determined by Maldivian customs regulations.

• Bangladesh:
• Regulatory Authority: Directorate General of Drug Administration (DGDA).
• Import Registration Process: Requires submission of detailed product information, including quality and clinical data, for DGDA's approval.
• Estimated Timeline: Typically 6 to 9 months, contingent on the thoroughness of the application and DGDA's review schedule.
• Import Tariff/Duty: Pharmaceuticals under HS Code 30049099 are subject to import duties as per Bangladesh's customs tariff, with rates varying based on product classification and trade agreements.

• Lebanon:
• Regulatory Authority: Ministry of Public Health (MOPH).
• Import Registration Process: Involves submission of a comprehensive dossier, including manufacturing and clinical data, for MOPH's evaluation and approval.
• Estimated Timeline: Approximately 6 to 12 months, depending on the completeness of the application and MOPH's review process.
• Import Tariff/Duty: Pharmaceutical products under HS Code 30049099 are subject to import duties as per Lebanon's customs regulations, with rates varying based on product specifics and trade agreements.

Navigating these regulatory landscapes requires thorough preparation and adherence to each country's specific requirements to ensure successful market entry.

The demand for Osimertinib in importing countries is influenced by several key factors:

• Disease Prevalence: Osimertinib is primarily used to treat non-small cell lung cancer (NSCLC) with specific genetic mutations. The prevalence of NSCLC in countries like Brazil and the United Kingdom drives the need for effective treatments, thereby increasing demand for Osimertinib.

• Government Healthcare Programs: Initiatives aimed at improving cancer care, such as Brazil's National Cancer Institute (INCA) programs and the UK's National Health Service (NHS) cancer treatment protocols, facilitate access to advanced therapies like Osimertinib.

• Universal Health Coverage Expansion: Countries expanding their health coverage, including the Maldives and Bangladesh, are incorporating more comprehensive cancer treatments into their healthcare systems, leading to increased procurement of medications like Osimertinib.

• WHO Essential Medicines List Procurement: Inclusion of cancer treatments in the WHO Essential Medicines List encourages countries to procure these medications to meet international healthcare standards.

• Tender-Based Purchasing: Many countries utilize tender systems for pharmaceutical procurement, allowing for bulk purchasing of medications like Osimertinib, which can lead to cost reductions and increased accessibility.

With 50 buyers across 8 countries, the market for Osimertinib imported from India demonstrates a diverse and growing demand, driven by the need for effective cancer treatments and the expansion of healthcare services.

The importation of Osimertinib from India involves various buyer segments, each with distinct purchasing behaviors:

• Hospital Groups: Entities like the Indira Gandhi Memorial Hospital in the Maldives fall into this category. They procure Osimertinib directly to meet patient needs, often placing orders based on current demand and treatment protocols. Their purchasing patterns are typically consistent, aligning with patient intake and treatment schedules.

• Distributors: Buyers such as "To the Concern Person" in Brazil and Incepta Pharmaceuticals Ltd in Bangladesh act as intermediaries, supplying Osimertinib to healthcare providers and pharmacies. They tend to place larger, periodic orders to maintain inventory levels and meet market demand.

• Individual Buyers: Several Brazilian buyers, including "Concern Person Wanilda De," "To The," and "Guilherme Martins De Almeida," appear to be individual purchasers. Their orders are typically smaller and less frequent, likely driven by personal or immediate community needs.

Understanding these segments is crucial for tailoring marketing strategies and supply chain logistics to effectively meet the diverse demands of each buyer type.

Importing Osimertinib into the top five countries involves navigating specific regulatory frameworks:

• Brazil:
• Regulatory Authority: Agência Nacional de Vigilância Sanitária (ANVISA).
• Import Registration Process: Requires submission of a comprehensive dossier, including clinical data and manufacturing details, followed by ANVISA's evaluation and approval.
• Estimated Timeline: Approximately 6 to 12 months, depending on the completeness of the application and ANVISA's review workload.
• Import Tariff/Duty: Pharmaceutical products under HS Code 30049099 are subject to a standard import duty, which may vary based on trade agreements and specific product classifications.

• United Kingdom:
• Regulatory Authority: Medicines and Healthcare products Regulatory Agency (MHRA).
• Import Registration Process: Requires a Marketing Authorization (MA), involving submission of quality, safety, and efficacy data.
• Estimated Timeline: Typically 6 to 12 months, subject to the complexity of the application and MHRA's assessment process.
• Import Tariff/Duty: Medicaments under HS Code 30049099 are generally subject to the UK's standard import duties, with specific rates depending on trade agreements and product specifics.

• Maldives:
• Regulatory Authority: Maldives Food and Drug Authority (MFDA).
• Import Registration Process: Involves submission of product dossiers, including manufacturing and clinical data, for MFDA's evaluation.
• Estimated Timeline: Approximately 3 to 6 months, depending on the completeness of the submission and MFDA's review process.
• Import Tariff/Duty: Pharmaceuticals under HS Code 30049099 may be subject to import duties, with rates determined by Maldivian customs regulations.

• Bangladesh:
• Regulatory Authority: Directorate General of Drug Administration (DGDA).
• Import Registration Process: Requires submission of detailed product information, including quality and clinical data, for DGDA's approval.
• Estimated Timeline: Typically 6 to 9 months, contingent on the thoroughness of the application and DGDA's review schedule.
• Import Tariff/Duty: Pharmaceuticals under HS Code 30049099 are subject to import duties as per Bangladesh's customs tariff, with rates varying based on product classification and trade agreements.

• Lebanon:
• Regulatory Authority: Ministry of Public Health (MOPH).
• Import Registration Process: Involves submission of a comprehensive dossier, including manufacturing and clinical data, for MOPH's evaluation and approval.
• Estimated Timeline: Approximately 6 to 12 months, depending on the completeness of the application and MOPH's review process.
• Import Tariff/Duty: Pharmaceutical products under HS Code 30049099 are subject to import duties as per Lebanon's customs regulations, with rates varying based on product specifics and trade agreements.

Navigating these regulatory landscapes requires thorough preparation and adherence to each country's specific requirements to ensure successful market entry.

The demand for Osimertinib in importing countries is influenced by several key factors:

• Disease Prevalence: Osimertinib is primarily used to treat non-small cell lung cancer (NSCLC) with specific genetic mutations. The prevalence of NSCLC in countries like Brazil and the United Kingdom drives the need for effective treatments, thereby increasing demand for Osimertinib.

• Government Healthcare Programs: Initiatives aimed at improving cancer care, such as Brazil's National Cancer Institute (INCA) programs and the UK's National Health Service (NHS) cancer treatment protocols, facilitate access to advanced therapies like Osimertinib.

• Universal Health Coverage Expansion: Countries expanding their health coverage, including the Maldives and Bangladesh, are incorporating more comprehensive cancer treatments into their healthcare systems, leading to increased procurement of medications like Osimertinib.

• WHO Essential Medicines List Procurement: Inclusion of cancer treatments in the WHO Essential Medicines List encourages countries to procure these medications to meet international healthcare standards.

• Tender-Based Purchasing: Many countries utilize tender systems for pharmaceutical procurement, allowing for bulk purchasing of medications like Osimertinib, which can lead to cost reductions and increased accessibility.

With 50 buyers across 8 countries, the market for Osimertinib imported from India demonstrates a diverse and growing demand, driven by the need for effective cancer treatments and the expansion of healthcare services.